]>
IRCT20211118053093N5 IRCT 2023-06-25 Shiraz University of Medical Sciences Memantine in treatment of OCD Memantine augmentation of escitalopram in treatment of executive function among patients with OCD, a Double-blind placebo controlled randomized clinical trial 2023-07-23 anticipated 60 Complete https://irct.ir/trial/70829 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: After gathering the patients randomization will be performed by main researcher by using random number table. The patients will be divided into 2 groups which everyone contains 30 patiens, Blinding description: Participants do not know which group they are in. The data analyser does not know which group it is analysing. The number of weeks of drug use is the same, so the patient is blinded to the type of treatment.Data analysis is given only data and does not know what treatment was done for witch group. 2 Obsessive-Compulsive Disorder. Intervention 1: Control group: In the control group, escitalopram starts with a dose of 5 mg per day and after 4 weeks the dose is increased to 10 mg per day and continues this way until the end of 16 weeks. This group receives placebo along with escitalopram. Intervention 2: Intervention group: receives escitalopram in the same way as the control group. This group receives memantine at a dose of 10 mg per day along with escitalopram. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information
public Leila Razeghian Jahromi
13 km Shiraz-Isfahan, Ostad Mohrari Hospital
Shiraz Iran (Islamic Republic of) 71441-13331 +98 71 3260 5701 leilarazeghian1366@gmail.com Shiraz University of Medical Sciences scientific Leila Razeghian Jahromi
13 km Shiraz-Isfahan, Ostad Mohrari Hospital
Shiraz Iran (Islamic Republic of) 71441-13331 +98 71 3260 5701 leilarazeghian1366@gmail.com Shiraz University of Medical Sciences Iran (Islamic Republic of) OCD diagnosis based on DSM-V criteria Y-BOCS score equal or more than 18 no limit no limit Both Drug abuse Pregnancy Medical problems F42 Obsessive-compulsive disorder Treatment - Drugs Treatment - Drugs Control group: In the control group, escitalopram starts with a dose of 5 mg per day and after 4 weeks the dose is increased to 10 mg per day and continues this way until the end of 16 weeks. This group receives placebo along with escitalopram. Intervention group: receives escitalopram in the same way as the control group. This group receives memantine at a dose of 10 mg per day along with escitalopram. Yale-Brown Obsessive Compulsive Scale score. Timepoint: Week 0, 4, 8 ,12, and 16. Method of measurement: Yale-Brown Obsessive Compulsive Scale questionnaire. Barkley Deficits in Executive Functioning Scale score. Timepoint: Week 0 and 16. Method of measurement: Barkley Deficits in Executive Functioning Scale questionnaire. Shiraz University of Medical Sciences Approved 2023-06-10 Ethics committee of Shiraz University of Medical Sciences Kilometer 13 of Shiraz-Isfahan highway, Ostad Mohrari Hospital Shiraz Fars Iran (Islamic Republic of)